Faslodex Advanced Breast Cancer Local Chinese Study
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment
compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.